55 Corporate Drive
63 articles with Sanofi
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
New data at ASCO include more than double the patients previously reported; median overall survival still not reached with a median follow-up of up to 17 months
Sanofi's oncology franchise and robust pipeline will be featured at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, delivering against a renewed strategy to address difficult-to-treat and difficult-to-eradicate cancers, including certain types of multiple myeloma, skin cancer, breast cancer, and lung cancer.
Individualised Extended Half-life Factor Replacement Therapy Controls Haemostasis in Orthopaedic Surgery
Sobi™ and Sanofi will present data demonstrating that Elocta® and Alprolix® can provide perioperative haemostatic control across a wide spectrum of major and minor surgeries in subjects of all ages with severe haemophilia A and B respectively.
Only biologic approved in the EU for severe asthma with type 2 inflammation, as characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO)
Relapsing MS Patients Who Received Aubagio® (teriflunomide) Experienced a Reduced Risk of Relapse Regardless of Prior Treatment Status in a Post-Hoc Analysis
These results will be presented this week during the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.
FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization
Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause
First-quarter sales(2) growth driven by Specialty Care, Vaccines and strong contribution from Emerging Markets
Sanofi continues its commitment to helping reduce cost burden for people living with diabetes with first-ever insulin savings program
The companies are currently advancing programs in oncology and autoimmune disease.
Alnylam to Advance Selected Investigational Asset in an Undisclosed Rare Genetic Disease Through the End of IND-Enabling Studies
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
Conference call and webcast scheduled for 8:00 a.m. Eastern Time
Multinational Biotech company quickly achieves data security and compliance objectives with Rubrik Cloud Data Management
Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis
Sanofi, Lead Pharma’s collaborative partner in the development of SAR441169, successfully initiated first human dosing with this novel RORγt Inverse Agonist candidate treatment
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attack
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that four new sub-analyses from the Praluent® (alirocumab) ODYSSEY OUTCOMES cardiovascular (CV) outcomes trial will be presented at the American College of Cardiology's 68th Annual Scientific Session (ACC.19), held March 16-18, in New Orleans, LA.
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents - March 12, 2019
Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis In a Phase 3 trial, Dupixent significantly reduced the extent and severity of disease and itching, and helped adolescents achieve clearer skin [12-March-2019] TARRYTOWN, N.Y. and CAMBRIDGE, Mass. , March 12, 2019 /PRNewswir
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents - March 11, 2019
In a Phase 3 trial, Dupixent significantly reduced the extent and severity of disease and itching, and helped adolescents achieve clearer skin
Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for Dupixent® in asthma.
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the companies will present a diverse set of clinical and real-world data at the 2019 American Academy of Dermatology Annual Meeting from March 1 to 5 in Washington, D.C.